Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 15,375,175 shares traded hands during mid-day trading, an increase of 6% from the previous session's volume of 14,481,065 shares.The stock last traded at $5.92 and had previously closed at $5.37.

Analyst Ratings Changes

RXRX has been the subject of several recent analyst reports. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley lowered their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Price Performance

The stock has a 50 day moving average of $4.83 and a two-hundred day moving average of $6.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market capitalization of $2.23 billion, a P/E ratio of -3.57 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the previous year, the firm posted ($0.39) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 7.2% compared to the same quarter last year. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares during the last quarter. Stratos Wealth Partners LTD. bought a new position in Recursion Pharmaceuticals during the fourth quarter worth $112,000. New Republic Capital LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at $179,000. Values First Advisors Inc. grew its position in Recursion Pharmaceuticals by 49.1% in the 4th quarter. Values First Advisors Inc. now owns 89,775 shares of the company's stock worth $607,000 after purchasing an additional 29,552 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Recursion Pharmaceuticals by 7.6% during the 4th quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock worth $2,258,000 after purchasing an additional 23,564 shares during the period. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.